Holen Sie sich die Stockscreener-App
87.77
0.56%
0.47
Incyte Corp Aktie (INCY) Neueste Nachrichten
Does Incyte Corporation show high probability of reboundPortfolio Profit Report & Fast Moving Stock Watchlists - newser.com
Incyte: Strong Growth, Margin Expansion, And Low Valuation - Seeking Alpha
Will Incyte Corporation (ICY) stock enhance shareholder valueTrade Signal Summary & Intraday High Probability Alerts - newser.com
Incyte Claims Sun Pharma's Alopecia Drug Launch Violates IP - Law360
Can a trend reversal in Incyte Corporation lead to recoveryEarnings Overview Summary & Fast Momentum Stock Entry Tips - newser.com
Is Incyte Corporation (ICY) stock among top earnings playsWeekly Volume Report & High Conviction Buy Zone Picks - newser.com
Incyte Corp. Stock Underperforms Monday When Compared To Competitors - 富途牛牛
Incyte (INCY) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Incyte's Quarterly Earnings Preview: What You Need to Know - inkl
Real time alert setup for Incyte Corporation performance2025 Winners & Losers & Free Community Supported Trade Ideas - newser.com
Is Incyte Corporation (ICY) stock undervalued by metricsWeekly Trend Summary & Safe Capital Investment Plans - newser.com
Is Incyte Corporation (ICY) stock dividend growth reliable2025 Breakouts & Breakdowns & Growth Oriented Trading Recommendations - newser.com
What’s next for Incyte Corporation stock priceMarket Sentiment Report & Real-Time Buy Signal Notifications - newser.com
Can Incyte Corporation (ICY) stock attract analyst upgradesQuarterly Earnings Summary & Weekly Watchlist for Hot Stocks - newser.com
Assessing Incyte’s Share Price After Recent FDA Approval and Strong 2024 Gains - Yahoo Finance
Are You Looking for a Top Momentum Pick? Why Incyte (INCY) is a Great Choice - sharewise.com
Multi asset correlation models including Incyte Corporation2025 Price Targets & Precise Trade Entry Recommendations - newser.com
Incyte to Report Third Quarter 2025 Financial Results on October 28 - MyChesCo
Lobbying Update: $80,000 of INCYTE CORPORATION lobbying was just disclosed - Quiver Quantitative
Incyte (INCY) Reports Encouraging Clinical Trial Data at ESMO Co - GuruFocus
Incyte at ESMO Congress 2025: Strategic Focus on Tumor Programs - Investing.com
Incyte’s cancer drug candidates show promising results in trials - Investing.com
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma - The AI Journal
What technical charts say about Incyte Corporation stockLong Setup & Long-Term Safe Investment Plans - nchmf.gov.vn
Is Incyte Corporation stock a defensive play in 20252025 Big Picture & Reliable Entry Point Trade Alerts - nchmf.gov.vn
Bollinger, Credo, Ambarella, Cipher, Incyte: Insider Moves Unveiled! - TipRanks
Is Incyte Corporation (ICY) stock a defensive play amid uncertaintyWeekly Trend Summary & Real-Time Volume Trigger Notifications - nchmf.gov.vn
How Incyte Corporation stock performs in rising dollar environmentMarket Performance Summary & Proven Capital Preservation Tips - newser.com
InvestingPro’s Fair Value model captures 63% gain in Incyte shares By Investing.com - Investing.com
Will Incyte Corporation (ICY) stock see insider accumulationMarket Volume Report & Free Low Drawdown Momentum Trade Ideas - newser.com
How Incyte Corporation stock responds to policy changesTrade Volume Report & Consistent Return Strategy Ideas - newser.com
Incyte (INCY) Stock Is Up, What You Need To Know - Barchart.com
Incyte Corporation stock hits 52-week high at 88.78 USD - Investing.com
Incyte (INCY) Price Target Lifted on CALR Antibody Program Optimism - MSN
Can Incyte Corporation rally from current levels2025 Top Gainers & Reliable Price Breakout Alerts - newser.com
Sjogren’s Syndrome Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Gilead Sciences, Incyte Corp, Novartis, GlaxoSmithKline, Janssen Research & Development, LLC - Barchart.com
Sjogren's Syndrome Market Insights Highlight Expanding - openPR.com
Incyte Canada Announces Health Canada approval of Opzelura® (Ruxolitinib) Cream for the Treatment of Atopic Dermatitis in Children Ages 2-11 - Yahoo
Using Python tools to backtest Incyte Corporation strategiesMarket Movers & Fast Entry Momentum Trade Alerts - newser.com
Incyte's (INCY) EVP and General Counsel Sold 4,100 Shares for $352,000 - The Globe and Mail
Incyte stock price target raised to $76 from $68 at UBS on valuation By Investing.com - Investing.com South Africa
Incyte stock price target raised to $76 from $68 at UBS on valuation - Investing.com India
How ESMO Congress Spotlight on Early Cancer Drugs Could Influence Incyte’s (INCY) Investment Outlook - Yahoo Finance
Incyte Corp. stock rises Monday, still underperforms market - MarketWatch
Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025 - BioSpace
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):